Literature DB >> 18543578

The influence of a newly developed quinolone: antofloxacin, on CYP activity in rats.

Xiao Xu1, Hai-Yan Liu, Li Liu, Lin Xie, Xiao-Dong Liu.   

Abstract

To investigate a newly developed quinolone antibiotics, the effect of antofloxacin hydrochloride on cytochrome P450 isoforms in rats was examined. A cocktail approach was adopted. Theophylline (CYP1A2), midazolam (CYP3A), chlorzoxazone (CYP2E1), dextromethorphan (CYP2D6), omeprazole (CYP2C19) and diclofenac (CYP2C9) were used as probes in the study, and own control was adopted. In Protocol 1, probes were given to rats simultaneously by co-administration with antofloxacin. The blood samples were obtained at designated time, and plasma concentrations of the six probes were determined by LC-MS. The pharmacokinetic parameters were calculated and compared in experimental groups in the absence and presence of antofloxacin. The result showed that the presence of antofloxacin resulted in a significant increase in theophylline values of AUC0-T and t1/2 (PAUC0-T = 0.0004 vs control Pt1/2 = 0.005 vs control), indicating that antofloxacin delayed the clearance of theophylline. In Protocol 2, the probes' pharmacokinetic parameters were compared in rats that received six probes before and after 14.5 days of consecutive administration of antofloxacin (15 mg x kg(-1), given orally, twice daily). The results suggested that the AUC0-T of chlorzoxazone was significantly decreased (P = 0.024), while that of dextromethorphan was significantly increased (P = 0.027). In conclusion, these results indicated that antofloxacin may inhibit the activity of CYP1A2, thus delaying the clearance of its substrates, and may have a slight inhibitory effect on CYP2D6 as well as an inductive effect on CYP2E1 following chronic administration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18543578     DOI: 10.1007/BF03191012

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  12 in total

1.  Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus.

Authors:  G T Tucker; J B Houston; S M Huang
Journal:  Clin Pharmacol Ther       Date:  2001-08       Impact factor: 6.875

Review 2.  "Cocktail" approaches and strategies in drug development: valuable tool or flawed science?

Authors:  Honghui Zhou; Zeen Tong; James F McLeod
Journal:  J Clin Pharmacol       Date:  2004-02       Impact factor: 3.126

3.  Influence of gatifloxacin, a new quinolone antibacterial, on pharmacokinetics of theophylline.

Authors:  Y. Niki; K. Hashiguchi; Naoyuki Miyashita; Masamitsu Nakajima; Toshiharu Matsushima
Journal:  J Infect Chemother       Date:  1999-09       Impact factor: 2.211

Review 4.  Overview of enzymes of drug metabolism.

Authors:  U A Meyer
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

5.  Enoxacin raises plasma theophylline concentrations.

Authors:  W J Wijnands; C L van Herwaarden; T B Vree
Journal:  Lancet       Date:  1984-07-14       Impact factor: 79.321

6.  A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study.

Authors:  Ashish Sharma; Sylvie Pilote; Pierre M Bélanger; Marie Arsenault; Bettina A Hamelin
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

7.  The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes.

Authors:  Magnus Christensen; Katarina Andersson; Per Dalén; Rajaa A Mirghani; Gary J Muirhead; Anna Nordmark; Gunnel Tybring; Anneli Wahlberg; Umit Yaşar; Leif Bertilsson
Journal:  Clin Pharmacol Ther       Date:  2003-06       Impact factor: 6.875

8.  Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro.

Authors:  U Fuhr; E M Anders; G Mahr; F Sörgel; A H Staib
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 9.  Probing the world of cytochrome P450 enzymes.

Authors:  Reginald F Frye
Journal:  Mol Interv       Date:  2004-06

10.  Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".

Authors:  Siwaporn Chainuvati; Anne N Nafziger; J Steven Leeder; Andrea Gaedigk; Gregory L Kearns; Edward Sellers; Yanhua Zhang; Angela D M Kashuba; Elizabeth Rowland; Joseph S Bertino
Journal:  Clin Pharmacol Ther       Date:  2003-11       Impact factor: 6.875

View more
  3 in total

1.  Inhibitory effects of wogonin on catalytic activity of cytochrome P450 enzyme in human liver microsomes.

Authors:  Tingting Li; Ning Li; Qinglong Guo; Hui Ji; Di Zhao; Shan Xie; Xiaonan Li; Zhixia Qiu; Deen Han; Xijing Chen; Qidong You
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-06-29       Impact factor: 2.441

2.  Effects of fish CYP inducers on difloxacin N-demethylation in kidney cell of Chinese idle (Ctenopharyngodon idellus).

Authors:  Ling Zhi Yu; Xian Le Yang; Xiang Ling Wang; Wen Juan Yu; Kun Hu
Journal:  Fish Physiol Biochem       Date:  2009-08-15       Impact factor: 2.794

3.  Chronic administration of caderofloxacin, a new fluoroquinolone, increases hepatic CYP2E1 expression and activity in rats.

Authors:  Li Liu; Ming-xing Miao; Ze-yu Zhong; Ping Xu; Yang Chen; Xiao-dong Liu
Journal:  Acta Pharmacol Sin       Date:  2016-02-01       Impact factor: 6.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.